News
First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...
The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...
Mar. 24, 2025 — A comprehensive study shows that people with fatty liver disease have almost twice the mortality rate of the general population. They have an increased risk of dying from both ...
Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...
GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening ...
Further imaging of the abdomen and pelvis identified a 14 cm left renal mass and multiple low-density hepatic lesions. A liver biopsy confirmed a PAX-8 and CD10 positive carcinoma, consistent with ...
Malnutrition adversely affects outcomes among patients with liver disease. Protein and fiber supplementation, a late-evening snack and coffee consumption are among recommendations. ACG released ...
Liver disease encompasses a range of conditions that affect the liver, an essential organ involved in digestion, metabolism, and ridding the body of toxins. Common symptoms of liver disease ...
18d
New Scientist on MSNDrugs like Wegovy can be effective at treating fatty liver diseaseSemaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic dysfunction-associated steatohepatitis (MASH) ...
The diabetes and weight loss drug semaglutide may also reverse signs of liver disease. That’s the headline result of a new clinical trial that tested the popular medication in patients with MASH ...
At least three people were shot to death and several others were injured in a mass shooting in Sweden's Uppsala on Tuesday. The incident reportedly occurred near Vaksala Square around midday, ...
Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results